Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00325182 · ClinicalTrials.gov registry record · Phase 4

The Effects of Levetiracetam on Alcohol Dependent Subjects

A Phase 4 study of Alcoholism, sponsored by Boston University.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT00325182 is a Phase 4 study of Alcoholism that has completed, run by Boston University. The registered enrollment target is 40 participants, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00325182, a Phase 4 study of Alcoholism, has completed, sponsored by Boston University.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This study will attempt to examine whether Levetiracetam (Keppra (TM)) can help people with alcohol dependence cut down on their alcohol consumption. In addition, the investigation will assess the effectiveness of Keppra on reducing withdrawal symptoms post alcohol cessation. Matched group of historical controls of alcohol dependent patients receiving placebo will be used for comparison.Based on the mechanism of action of Keppra we hypothesize that it may be effective in promoting abstinence and reducing drinking behavior in alcohol dependent patients.

Conditions Studied

Interventions

  • DRUG Levetiracetam
  • OTHER Historical controls

Study Locations (1)

Massachusetts

  • Boston University Dept of Psychiatry Clinical Studies Unit - Boston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2006-01
Est. Completion 2009-10
Phase Phase 4

Sponsor

Boston University

185 total trials

What the Registry Record Tells You About NCT00325182

The ClinicalTrials.gov registry entry for NCT00325182 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (89% lower). The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Levetiracetam is the first listed.

NCT00325182 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00325182 about?

NCT00325182 is a clinical study titled "The Effects of Levetiracetam on Alcohol Dependent Subjects". This study will attempt to examine whether Levetiracetam (Keppra (TM)) can help people with alcohol dependence cut down on their alcohol consumption. In addition, the investigation will assess the effectiveness of Keppra on reducing withdrawal symptoms post alcohol cessation. Matched group of histor...

What is the current status of trial NCT00325182?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2006-01. Estimated completion is 2009-10.

What conditions does trial NCT00325182 study?

This clinical trial studies the following conditions: Alcoholism.

What interventions are being tested in trial NCT00325182?

The interventions under investigation include: Levetiracetam (DRUG), Historical controls (OTHER).

Who is sponsoring clinical trial NCT00325182?

This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00325182 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcoholism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.